C-Path Forms Drug Testing Pact
The Tucson-based Critical Path Institute on Thursday announced an unprecedented agreement with eight major pharmaceutical companies to share drug-testing methods in an effort to improve drug safety.
Related Posts
-
C-Path Receives COA Qualification from FDA for the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) -
Critical Path Institute Receives Regulatory Support for Liver Injury Biomarker -
C-Path and FARA announce collaborative data aggregation project for Friedreich’s ataxia -
miR-122 An Exploratory Biomarker of Liver Injury: An Industry Perspective on the State of the Science and Experiences Pre-Clinically and Clinically -
New CDISC Data Standard Aids Development of Therapies for Ebola Virus